Elucid Raises $55M Series D for Cardiovascular AI

Elucid raised a $55M Series D to expand a cardiovascular imaging platform built around a more specific clinical question: not only where a coronary artery narrows, but what the plaque inside it may reveal about risk.

The oversubscribed financing includes a new, unnamed large medical-technology company that Elucid says is now its fourth publicly traded strategic investor. IAG Capital Partners and Elevage Medical Technologies also participated. Elucid did not identify a lead investor or disclose a valuation.

The Boston company says the round brings its total funding to approximately $185M. The capital will support commercialization of its imaging platform, continued AI research and development, and landmark clinical studies. Its FDA-cleared Plaque-IQ product is already in market, while its FFR-CT product remains under FDA review.

From Artery Narrowing to Plaque Biology

Coronary CT angiography gives clinicians a noninvasive view of the coronary arteries. Traditional assessment often centers on stenosis, or how much the vessel has narrowed. That matters, but it does not fully describe the plaque's composition or the physiology around a specific lesion.

Elucid's platform is designed to add that detail. Plaque-IQ analyzes CCTA images to quantify and characterize plaque, creating a view of the disease burden that can support more individualized decisions. The FDA's 510(k) record lists Elucid PlaqueIQ under K241524 and records a substantially equivalent decision dated September 12, 2024.

The company is also developing FFR-CT, which estimates whether a narrowing is materially restricting blood flow. Elucid describes the two products as part of one platform: plaque characterization provides the anatomical and biological picture, while FFR-CT adds a physiological view. FFR-CT is under FDA review and should not be treated as cleared or commercially available in the United States.

That regulatory distinction is central to the Series D. Elucid is funding growth around one cleared product while trying to expand the platform with another. The outcome will depend on whether clinicians can use those measurements together inside a real CCTA workflow without adding enough friction to erase the value.

What the $55M Series D Funds

Elucid's official Series D announcement identifies three uses for the financing: broader commercialization, continued AI research and development, and landmark clinical studies. Each addresses a different part of the adoption problem.

Commercialization means more than adding sales capacity. Imaging software must fit radiology and cardiology workflows, reach physicians in a usable format, secure reimbursement, and generate evidence that health systems can evaluate. Elucid reports that positive coverage policies now reach approximately 70% of insured U.S. lives. That is a company-reported coverage measure, not proof that the product has achieved equivalent utilization across those lives.

The strategic composition of the round is also notable. Elucid says the unnamed new participant is a large medical-technology company and its fourth publicly traded strategic investor. The investor's identity and intended operating relationship are not public, so the announcement supports a signal of strategic interest without supporting claims about a commercial partnership, distribution agreement, or acquisition path.

IAG Capital Partners and Elevage Medical Technologies bring another layer of continuity. Elevage led Elucid's $80M Series C in November 2023. Elucid also announced a $27M Series B in 2022 and an earlier $8M Series A. The company's current approximately $185M total is the authoritative figure; public round announcements do not support a precise valuation.

The Evidence Program Behind the Platform

Clinical imaging companies have to show more than technical accuracy. They need evidence that the information reaches the right decision point and helps physicians distinguish meaningful risk from incidental detail.

Elucid's AI-PREDICT program is designed around that lesion-level question. The company announced the first patient in July 2026 for a retrospective, international, multicenter study planning approximately 1,000 subjects across more than 20 sites. The study is intended to examine whether plaque characteristics can identify lesions associated with future adverse cardiovascular events.

Those details describe the study's ambition and design, not its results. The Series D gives Elucid more resources to complete that evidence work, but the clinically important proof will come from validated performance, peer-reviewed outcomes, and adoption patterns after physicians see how the platform behaves across patient populations and care settings.

Why the Lesion-Level Question Matters

The World Health Organization estimates that cardiovascular diseases caused 19.8M deaths in 2022, roughly 32% of deaths worldwide. That scale explains the pressure to detect risk earlier, but it does not make every imaging signal equally useful.

A physician needs to know what changes because a measurement exists. Does the plaque profile alter therapy? Does physiology change the decision to intervene? Can the result be explained to the patient and compared over time? Does the workflow reduce avoidable invasive testing without missing disease that needs treatment?

Elucid is positioning its platform around those decisions. President and CEO Kelly Huang leads the company as it moves from product clearance and technical development into a broader commercial phase. The work now sits at the intersection of regulatory execution, reimbursement, clinical evidence, and physician trust.

What the Round Signals

The $55M Series D is not simply another vote for healthcare AI. It is capital for a narrower transition: turning detailed plaque analysis from an impressive image-processing capability into a repeatable part of cardiovascular care.

The next evidence will be operational. Elucid must expand use of Plaque-IQ, advance FFR-CT through FDA review, complete clinical studies, and show that more information at the lesion level produces clearer decisions rather than another layer of data.

Cardiology has become exceptionally good at seeing the artery. Elucid's opportunity is to make the disease inside it harder to overlook and easier to act on.